[CPRX] Catalyst Pharmaceuticals, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 1.09 Change: 0 (0%)
Ext. hours: Change: 0 (0%)

chart CPRX

Refresh chart

Strongest Trends Summary For CPRX

CPRX is in the medium-term up 27% in 1 month. In the long-term up 138% in 4 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Catalyst Pharmaceutical Partners, Inc. operates as development-stage specialty pharmaceutical company. The company focuses on the development and commercialization of novel prescription drugs targeting rare (orphan) neuromuscular and neurological diseases and disorders. Its principal product candidate is Firdapse, a proprietary form of amifampridine phosphate, which is in Phase III clinical trial for the treatment of Lambert-Eaton Myasthenic Syndrome. The company also develops CPP-115, a vigabatrin analog to treat infantile spasms and epilepsy, as well as other neurological conditions associated with reduced GABAergic signaling, such as post-traumatic stress disorder and Tourette syndrome. Catalyst Pharmaceutical Partners, Inc. has strategic collaboration agreement with BioMarin. The company was founded in 2002 and is based in Coral Gables, Florida.

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-22.5% ROE-25.68% ROI
Current Ratio12.99 Quick Ratio Long Term Debt/Equity Debt Ratio0.09
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities36.06 M Cash From Investing Activities-40 K Cash From Operating Activities-3.79 M Gross Profit
Net Profit-5.41 M Operating Profit-4.29 M Total Assets76.05 M Total Current Assets75.97 M
Total Current Liabilities5.85 M Total Debt Total Liabilities9.43 M Total Revenue
Technical Data
High 52 week3.84 Low 52 week1.92 Last close2.88 Last change-1.03%
RSI77.42 Average true range0.13 Beta0.6 Volume310.27 K
Simple moving average 20 days11.78% Simple moving average 50 days18.31% Simple moving average 200 days-3.21%
Performance Data
Performance Week3.97% Performance Month16.13% Performance Quart3.23% Performance Half-3.03%
Performance Year-8.57% Performance Year-to-date50% Volatility daily3.02% Volatility weekly6.74%
Volatility monthly13.82% Volatility yearly47.87% Relative Volume298.06% Average Volume1.79 M
New High New Low

News

2019-03-19 18:16:19 | Edited Transcript of CPRX earnings conference call or presentation 19-Mar-19 12:30pm GMT

2019-03-19 17:23:00 | Why Catalyst Pharmaceuticals Stock Is Popping Today

2019-03-19 14:26:06 | Catalyst CPRX Reports Wider Q4 Loss, Focuses on Firdapse

2019-03-19 07:40:42 | The Daily Biotech Pulse: FDA Nod For Roche And Amphastar, Milestone Payment Kicks In For Affimed

2019-03-18 16:52:23 | Catalyst: 4Q Earnings Snapshot

2019-03-18 16:20:00 | Catalyst Pharmaceuticals Announces Fourth Quarter and Year-End 2018 Financial Results and Provides Corporate Update

2019-03-14 13:34:37 | The Catalyst Pharmaceuticals NASDAQ:CPRX Share Price Has Gained 181%, So Why Not Pay It Some Attention?

2019-03-11 08:03:00 | Catalyst Pharmaceuticals to Hold Fourth Quarter Financial Results and Corporate Update Conference Call and Webcast on Tuesday, March 19th, 2019

2019-02-28 13:44:28 | U.S. Senator Sanders urges FDA to allow older versions of $375,000 drug

2019-02-28 08:03:00 | Catalyst Pharmaceuticals Announces Support of Rare Disease Day 2019

2019-02-26 08:03:00 | Catalyst Pharmaceuticals Announces Publication of Phase 3 Clinical Trial Data for Firdapse® for the Treatment of Lambert-Eaton Myasthenic Syndrome

2019-02-21 14:28:05 | Catalyst Pharmaceuticals defends $375,000 drug price after Bernie Sanders rebuke

2019-02-21 09:00:00 | Catalyst Pharmaceuticals Responds to Letter from Senator Bernie Sanders

2019-02-11 14:58:05 | Catalyst Pharma sees net price of drug, once free, topping $300,000

2019-02-06 14:39:06 | Coral Gables company under fire for drug pricing says patient care is 'top priority'

2019-02-05 08:03:00 | Catalyst Pharmaceuticals to Present at the 21st Annual BIO CEO & Investor Conference

2019-02-04 10:34:04 | U.S. Senator Sanders asks why drug, once free, now costs $375k

2019-01-28 12:22:46 | What Kind Of Shareholders Own Catalyst Pharmaceuticals, Inc. NASDAQ:CPRX?

2019-01-04 08:03:00 | Catalyst Pharmaceuticals Announces Publication of Clinical Data from the Investigator-Sponsored Phase IIb Study Evaluating Firdapse® for the Treatment of MuSK Antibody Positive Myasthenia Gravis

2018-12-19 12:32:12 | Should You Buy Catalyst Pharmaceuticals, Inc. CPRX?

2018-12-18 11:40:00 | Catalyst Pharmaceuticals Announces Definitive Agreement with Endo for Vigabatrin Tablets

2018-12-14 11:42:37 | Does Catalyst Pharmaceuticals, Inc. NASDAQ:CPRX Have A Volatile Share Price?

2018-12-11 07:30:00 | Report: Exploring Fundamental Drivers Behind Sabre, Catalyst Pharmaceuticals, Renewable Energy Group, Luminex, Parker Drilling, and Apollo Endosurgery — New Horizons, Emerging Trends, and Upcoming Developments

2018-12-03 08:03:00 | Catalyst Pharmaceuticals Announces Conference Call to Discuss Commercialization Plan for Firdapse® amifampridine for Lambert-Eaton Myasthenic Syndrome LEMS

2018-11-30 17:42:00 | Why Catalyst Pharmaceuticals Stock Fell Again Today

2018-11-29 16:00:00 | Why Catalyst Pharmaceuticals Stock Is Sinking Today

2018-11-29 09:25:32 | FDA approves new drug developed by Coral Gables company

2018-11-29 08:33:01 | Catalyst's Firdapse Receives FDA Approval for Rare Disease

2018-11-29 06:50:00 | Today's Research Reports on Trending Tickers: Alliqua BioMedical and Catalyst Pharmaceuticals

2018-11-29 06:03:00 | FDA Approves Firdapse® amifampridine for the Treatment of Lambert-Eaton Myasthenic Syndrome LEMS

2018-11-28 18:36:26 | U.S. FDA approves Catalyst Pharma's rare disease drug

2018-11-27 16:12:28 | Catalyst Pharmaceuticals Announces Firdapse® amifampridine New Drug Application Continues Under Review

2018-11-20 08:39:01 | Do Options Traders Know Something About Catalyst CPRX Stock We Don't?

2018-11-08 17:37:28 | Edited Transcript of CPRX earnings conference call or presentation 8-Nov-18 1:30pm GMT

2018-11-07 18:35:34 | Catalyst: 3Q Earnings Snapshot

2018-11-07 16:19:20 | Catalyst Pharmaceuticals Announces Third Quarter 2018 Financial Results and Provides Corporate Update

2018-10-31 08:03:00 | Catalyst Pharmaceuticals to Hold Third Quarter Financial Results and Corporate Update Conference Call and Webcast on Thursday, November 8th, 2018

2018-10-10 07:30:00 | Market Trends Toward New Normal in AllianceBernstein Holding, Five9, Simpson Manufacturing, Green Plains, Catalyst Pharmaceuticals, and Commercial Vehicle Group — Emerging Consolidated Expectations, Analyst Ratings

2018-09-20 12:56:49 | Catalyst Pharmaceuticals Inc’s NASDAQ:CPRX Shift From Loss To Profit

2018-09-20 08:03:00 | Catalyst Pharmaceuticals to Participate in Two Upcoming Investor Conferences

2018-09-06 11:39:03 | Catalyst CPRX Up 16% Since Last Earnings Report: Can It Continue?

2018-08-30 18:51:07 | Healthcare Wiz Mitchell Blutt Bets Big on These 3 Biotech Stocks

2018-08-29 08:03:00 | Catalyst Pharmaceuticals to Present at Rodman & Renshaw’s 20th Annual Global Investment Conference

2018-08-22 19:03:37 | Why Catalyst Pharmaceuticals CPRX Is a $6 Stock

2018-08-08 06:30:00 | Catalyst Pharmaceuticals, Inc. to Host Earnings Call

2018-08-07 16:44:37 | Catalyst: 2Q Earnings Snapshot

2018-08-07 16:20:13 | Catalyst Pharmaceuticals Announces Second Quarter 2018 Financial Results and Provides Corporate Update

2018-08-06 08:03:00 | Catalyst Pharmaceuticals Expands Commercial Leadership Team

2018-08-01 08:03:00 | Catalyst Pharmaceuticals to Hold Second Quarter Financial Results and Corporate Update Conference Call and Webcast on Wednesday, August 8th, 2018

2018-08-01 07:30:00 | New Research Coverage Highlights Ladder Capital, Gibraltar Industries, Norwegian Cruise Line, Wolverine World Wide, Catalyst Pharmaceuticals, and Radius Health — Consolidated Revenues, Company Growth, and Expectations for 2018